Clinical Orthopaedics and Related Research: January 2011 - Volume 469 - Issue 1 - p 26–33 doi: 10.1007/s11999-010-1313-9 Symposium: Papers Presented at the Annual Meetings of the Knee Society

Methicillin-resistant Staphylococcus aureus in TKA Treated With Revision and Direct Intraarticular Antibiotic Infusion

Whiteside, Leo, A., MD1, 2, a; Peppers, Michael, PharmD3; Nayfeh, Tariq, A., MD, PhD4; Roy, Marcel, E., PhD2
Knee

Background Resistant organisms are difficult to eradicate in infected total knee arthroplasty. While most surgeons use antibiotic-impregnated cement in these revisions, the delivery of the drug in adequate doses is limited in penetration and duration. Direct infusion is an alternate technique.

 

Questions/purposes We asked whether single-stage revision and direct antibiotic infusion for infected TKA would control infection in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.

 

Methods We retrospectively reviewed 18 patients (18 knees) with MRSA with one-stage revision protocol that included débridement, uncemented revision of total knee components, and intraarticular infusion of 500 mg vancomycin via Hickman catheter once or twice daily for 6 weeks; we used no intravenous antibiotics after the first 24 hours. We monitored serum vancomycin levels to maintain levels between 3 and 10 μg/mL. Minimum followup was 27 months (range, 27-75 months). Mean followup was 62 months, (range, 27-96 months).

 

Results Infection was controlled at last followup in all but one patient with a recurrence of the MRSA. The patient was reoperated at 5 months; a necrotic bone fragment was removed, the knee was débrided and revised, and the antibiotic infusion protocol readministered. The patient remained free of infection 42 months postoperatively. At 2-year followup, the mean Knee Society score was 83. We observed no radiographic evidence of implant migration.

 

Conclusions One-stage revision and 6 weeks of intraarticular vancomycin administration controlled infection in MRSA infected TKA with no apparent complications.

 

Level of Evidence Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.


Link to article